3mg, 6 mg and 9 mg prolonged release tabletsPRESCRIBING INFORMATION
3 mg, 6 mg or 9 mg paliperidone.
Please refer to Summary of Product Characteristics (SmPC) before prescribing.
The INVEGA® SmPCs are available at:
Treatment of schizophrenia in adults, and adolescents 15 years and older.
Adults only: Treatment of schizoaffective disorder.
DOSAGE & ADMINISTRATION:
Adults (Schizophrenia and Schizoaffective disorder)
6 mg once daily in the morning with or without food (do not vary).Initial dose titration not required. Dosage adjustment, if indicated, only after clinical reassessment. Increments of 3 mg/day are recommended, generally at intervals of more than 4 days for schizoaffective disorder and more than 5 days for schizophrenia. Recommended range 3-12 mg for schizophrenia and 6-12 mg for schizoaffective disorder. Swallow tablets whole with liquid.
Adolescents 15 years and older (Schizophrenia)
3 mg once daily in the morning with or without food (do not vary). Maximum recommended daily doses for adolescents < 51 kg is 6 mg and ≥ 51 kg is 12 mg.
Adjust dose within recommended range (after clinical reassessment), in increments of 3 mg/day at > 5 day intervals. Swallow tablets whole with liquid.
The efficacy of INVEGA® in the treatment of schizophrenia in adolescents between 12 and 14 years old has not been established.
Elderly: Caution in elderly dementia patients with stroke risk factors.
Mild (crcl 50-80 ml/min): 3 mg once daily increasing to maximum of 6 mg once daily based on response and tolerability.
Moderate to Severe (crcl 10-50 ml/min): 3 mg every other day recommended initial dose in severe renal impairment. May be increased to 3 mg once daily after clinical reassessment. Do not use in patients with creatinine clearance below 10 ml/min.
Hepatic impairment: No dose adjustment for mild or moderate hepatic impairment. Caution in severe hepatic impairment.
Hypersensitivity to paliperidone, risperidone, or excipients.
SPECIAL WARNINGS & PRECAUTIONS:
Schizoaffective disorder: Monitor INVEGA® treated patients carefully for potential switch from manic to depressive symptoms.
Cardiovascular disease: Caution in patients with known cardiovascular disease, or family history of Q-T prolongation. INVEGA® may induce orthostatic hypotension in some patients. Use with caution in cardiovascular disease, cerebrovascular disease and conditions that predispose patient to hypotension.
Neuroleptic Malignant Syndrome: Discontinue all antipsychotics, including INVEGA® if symptoms/signs develop.
Tardive dyskinesia: If signs/symptoms appear, consider discontinuing all antipsychotics, including INVEGA®.
Leukopenia, neutropenia, and agranulocytosis: Events of leucopenia, neutropenia, and agranulocytosis reported with antipsychotics, including INVEGA® - additional monitoring or cessation of treatment may be required.
Weight gain: Monitor weight regularly.
Hyperprolactinaemia: Use with caution in patients with possible prolactin-dependent tumours.
Patients with diabetes mellitus/hyperglycaemia: Hyperglycaemia, diabetes mellitus, and exacerbation of pre-existing diabetes have been reported during treatment. Appropriate clinical monitoring is advisable.
Patients with seizures: Caution where there is a history of seizures/other conditions that potentially lower the seizure threshold.
Patients with dysphagia: Do not administer to patients with significant swallowing difficulty or known gastro-intestinal strictures.
Patients with decreased gastro-intestinal transit time: Reduced absorption of paliperidone may result.
Patients with renal impairment: See Dosage & Administration. Do not use in patients with creatinine clearance below 10 ml/min.
Patients with hepatic impairment: See Dosage & Administration. Caution in severe hepatic impairment.
Elderly patients with dementia: Use with caution in elderly dementia patients with risk factors for stroke.
Parkinson’s disease: Use with caution.
Priapism: Reported during post-marketing surveillance (incidence not known).
Body temperature regulation: Care when prescribing to patients experiencing conditions which may contribute to core body temperature elevation.
Venous Thromboembolism: Identify all possible risk factors for VTE before and during treatment and take preventive measures.
Anti-emetic effect: Observed in paliperidone preclinical studies; if occurs in human patients may mask signs and symptoms of overdosage with certain medicines, or of medical conditions such as intestinal obstruction, Reye’s syndrome, brain tumour etc.
Paediatric population: monitor sedative effect of INVEGA® closely (changing the time of administration may improve impact of sedation on patient). Potential effects of prolonged hyperprolactinemia- consider regular clinical evaluation of endocrinological status (height, weight, sexual maturation). Monitor regularly for extra-pyramidal symptoms, other movement disorders.
Intraoperative floppy iris syndrome (IFIS) has been observed during cataract surgery in patients treated with medicines with alpha1a-adrenergic antagonist effect, such as INVEGA®.
Lactose content (3 mg tablets only): Avoid in patients with rare hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
Very common: headache, insomnia, sedation/somnolence, parkinsonism, akathisia,
Common: bronchitis, upper respiratory tract infection, sinusitis, urinary tract infection, influenza, weight increased, increased appetite, weight decreased, decreased appetite, mania, agitation, depression, anxiety, dystonia, dizziness, dyskinesia, tremor, vision blurred, atrioventricular block, conduction disorder, electrocardiogram QT prolonged, bradycardia, tachycardia, orthostatic hypotension, hypertension, pharyngolaryngeal pain, cough, nasal congestion, abdominal pain, abdominal discomfort, vomiting, nausea, constipation, diarrhoea, dyspepsia, dry mouth, toothache, transaminases increased, pruritus, rash, musculoskeletal, pain, back pain, arthralgia, amenorrhoea, pyrexia, asthenia and fatigue.
Extrapyramidal Symptoms (EPS):
Schizophrenia: In clinical trials no difference observed between placebo and the 3 mg and 6 mg doses of INVEGA®. Dose-relatedness for EPS seen with higher INVEGA® doses (9 mg and 12 mg);
Schizoaffective disorder: higher rate of EPS versus placebo in clinical trials in all dose groups without clear dose relationship.
Hyperprolactinaemia: increased serum prolactin in 67% of INVEGA® treated subjects in schizophrenia clinical trials; however prolactin-related adverse events reported in 2% of subjects overall.
Weight gain: Schizophrenia clinical trials, similar incidence of weight gain (≥ 7%) for INVEGA® 3 mg and 6 mg compared with placebo; higher incidence of weight gain for INVEGA® 9 mg and 12 mg; in schizoaffective disorder trials, 5% of INVEGA® treated subjects had a bodyweight increase of ≥ 7% compared to 1% of placebo group.
Class effects: QT prolongation, ventricular arrhythmias, sudden unexplained death, cardiac arrest and Torsade de pointes may occur with antipsychotics. Cases of venous thromboembolism, including pulmonary embolism and deep vein thrombosis also reported. Rarely, drug withdrawal syndrome in neonates observed with antipsychotics.
Refer to SmPC for other side effects.
in a study conducted in elderly subjects with schizophrenia, safety profile was similar to non-elderly subjects.
Overall safety profile in studies involving adolescents 12 years and older with schizophrenia similar to adults except for the following adverse drug reactionss reported more frequently in INVEGA®-treated adolescents:
Very common: sedation/somnolence, parkinsonism, weight increase, upper respiratory tract infection, akathisia, and tremor.
Common: abdominal pain, galactorrhoea, gynaecomastia, acne, dysarthria, gastroenteritis, epistaxis, ear infection, blood triglyceride increased, vertigo.
Extrapyramidal Symptoms (EPS): incidence higher than placebo for all doses, and increased frequency at higher doses. Weight gain: higher incidence of ≥ 7% weight gain in INVEGA®-treated subjects versus placebo in short-term study (no clear dose relationship).
Prolactin: Adverse reactions suggestive of increased prolactin levels reported overall in 9.3% of subjects in an up to 2 year open label study.
INVEGA® should not be used during pregnancy unless clearly necessary.
INVEGA® should not be used while breastfeeding.
Caution prescribing INVEGA® with medicines that prolong QT interval e.g., class IA and class III antiarrhythmics, some antihistaminics, some other antipsychotics, some antimalarials.
Potential for INVEGA® to affect other medicines: Not expected to cause clinically important pharmacokinetic interactions with medicines metabolized by cytochrome P-450 isozymes. Use with caution in conjunction with: centrally acting medicines e.g. anxiolytics, antipsychotics, hypnotics, opiates, or alcohol; medicines known to lower seizure threshold i.e., phenothiazines, butyrophenones, clozapine, tricyclics, SSRI’s, tramadol, mefloquine etc; medicines capable of inducing orthostatic hypotension (an additive effect may be observed when INVEGA® is co-administered); levodopa and other dopamine agonists (paliperidone may antagonize their effect - use the lowest effective dose of each treatment if this combination must be prescribed e.g., end-stage Parkinson’s disease).No interaction study between INVEGA® and lithium has been performed, however pharmacokinetic interaction unlikely to occur.
Potential for other medicines to affect INVEGA®: Co-administration of INVEGA® once daily with carbamazepine 200 mg twice daily decreases plasma concentration of paliperidone by 37%. Re-evaluate/increase INVEGA® dose at carbemazepine initiation. Other P-gp inducers e.g., rifampicin, St. John’s wort may have similar effects. No indications from in vitro and in vivo studies that isozymes CYP2D6 and CYP3A4 are significant in the metabolism of paliperidone. Metoclopramide and other medicines affecting G.I. transit time may alter paliperidone absorption. Consider reducing INVEGA® dosage when co-administered with valproate (after clinical assessment). Do not use INVEGA® with oral risperidone as additive paliperidone exposure may occur.
Paediatric population: Interaction studies have only been performed in adults.
Refer to SmPC for full details of interactions.
LEGAL CATEGORY: POM.
PRESENTATIONS, PACK SIZES, MARKETING AUTHORISATION NUMBER(S) & BASIC NHS COSTS
|PRESENTATION(S)||PACK SIZE(S)||MARKETING AUTHORISATION NUMBER(S)||BASIC NHS COST(S)|
|3 mg prolonged release tablets||Blister pack 28 tablets||EU/1/07/395/001||£97.28|
|6 mg prolonged release tablets||EU/1/07/395/006||£97.28|
|9 mg prolonged release tablets||EU/1/07/395/011||£145.92|
MARKETING AUTHORISATION HOLDER: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium.
FURTHER INFORMATION IS AVAILABLE FROM: Janssen-Cilag Limited, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire HP12 4EG, UK.
Prescribing information last revised: 03/2018